Dr. Brian Confrey Mazzarella, MD

Dr. Mazzarella practices at Urology Austin in Austin, Texas.

Dr. Mazzarella's NPI, 1417265851, was assigned on September 20, 2010. Dr. Mazzarella graduated from Joe R. & Teresa Lozano Long School of Medicine in 2010. Dr. Mazzarella holds Texas license R5008.

Dr. Mazzarella's primary practice is Urology Austin, at 1020 W 34th St, Austin, TX 78705 in Travis County. The practice phone is (512) 256-3000.

Dr. Mazzarella's primary practice is Urology Austin in Austin, Texas. The medical group on file is Urology Austin. Dmand AI also links Dr. Mazzarella to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mazzarella practices. Vendor and product names are available with a free account.

Urology is Dr. Mazzarella's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Mazzarella is board certified in urology by the American Board of Urology. Dmand AI has Dr. Mazzarella's licenses on file in 2 states: Texas and Louisiana.

Dmand AI lists enlarged prostate, erectile dysfunction, testicular dysfunction and urinary endoscopy among the conditions Dr. Mazzarella treats.

CMS data shows 199 Medicare services from Dr. Mazzarella across 4 procedure codes in 2024, for 48 Medicare patients. Medicare paid $75,042 for them. Every service was in an office.

CMS counts 48 Medicare patients who saw Dr. Mazzarella in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mazzarella's median patient age at 72, with 6% women.

In 2024, Dr. Mazzarella wrote 63 Medicare Part D claims for 28 patients. 89% of them were for generic drugs. CMS names the drug for 24 of them, across 2 drugs with 11 or more claims each, at $331 in total drug cost. In 2023, CMS named 61 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Mazzarella for performance year 2024, reported as part of a group. Dr. Mazzarella accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Mazzarella, published from 2014 to 2024. 2014 was the busiest year, with 2. The most frequent topics are Ejaculation, Genetic Testing and Germ-Line Mutation. Dr. Mazzarella has published most often in J Urol. Dr. Mazzarella's most frequent co-authors are Laurence H. Belkoff, DO, Aaron D. Berger, MD and Richard Hugh Bevan-Thomas, MD.

Dmand AI links Dr. Mazzarella to 4 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Diseases, Prostatic Neoplasms and Prostatic Hyperplasia.

CMS Open Payments shows 1,422 general payments to Dr. Mazzarella from 34 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. NeoTract Inc. paid the most, $980,804.

Dr. Mazzarella graduated from Joe R. & Teresa Lozano Long School of Medicine in 2010.

Dr. Mazzarella is in network with 20 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.